KEYNOTE-716 trial brings to light the impressive efficacy of pembrolizumab as an adjuvant therapy for stage IIB or IIC melanoma.…
Browsing: KEYNOTE-716
Jason Luke, MD, FACP, a renowned medical professional affiliated with the University of Pittsburgh Medical Center (UPMC), recently conducted a…
ASCO 2022 Melanoma (American Society of Clinical Oncology) In-Depth Slides: MOASC Spotlight on Oncology I’ll do a brief reminder of…
ASCO 2022 Melanoma Overview: MOASC Spotlight  KEYNOTE-716 Study  Today, we talked about some of the exciting new discoveries…